Interstitial NanoSystems

Interstitial NanoSystems (INS) is an early-stage biotechnology company focused on developing advanced platforms for accessing and leveraging the interstitial fluid (ISF) for diagnostics and drug delivery. The company's core technology utilizes nano-scale systems and microneedle arrays to provide minimally invasive, continuous monitoring of biomarkers and precise delivery of therapeutics directly into the interstitium. By targeting the fluid-filled space between cells, INS aims to overcome the limitations of traditional blood-based diagnostics and systemic drug administration. Their primary focus areas include chronic disease management, particularly diabetes, where real-time monitoring and localized delivery can significantly improve patient outcomes.